Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014

Jia, Yijun; Sun, Chenbo; Liu, Zebing; Wang, Y. Lynn; Zhou, Xiaoyan

doi:10.18632/oncotarget.23285

Cited by 27 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nipple retraction, skin erythema, peaud'orange appearance, and nipple discharge are rare in PBL as compared with breast carcinoma. It may sometimes present as diffuse breast enlargement with edema and may mimic an inflammatory process [4,13,23]. The usual B symptoms seen with lymphomas such as fever, weight loss, and night sweats are rare with PBL.…”

Section: Discussionmentioning

confidence: 99%

“…reast involvement by lymphoma is very rare and presents as a primary breast tumor or as a secondary disease. Primary breast lymphoma (PBL) represents 1% of all non-Hodgkin's lymphoma, 2.2% of extranodal lymphomas, and approximately 0.04-0.5% of malignant breast tumors [1][2][3][4][5][6][7]. A limited number of cases have been reported in the literature so far.…”

mentioning

confidence: 99%

“…A limited number of cases have been reported in the literature so far. The most common histology is diffuse large B-cell lymphoma (DLBCL), although other less frequent diverse lymphoma subtypes have been reported [1][2][3][4][5][6][7][8][9][10].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Primary Breast Lymphoma: A Case Series and Review

Sonkaria¹,

Tanwar²,

Saxena³

et al. 2020

IJCR

View full text Add to dashboard Cite

The primary breast lymphoma (PBL) is a rare manifestation of extranodal non-Hodgkin's lymphoma. The clinical features are indistinguishable to that of breast carcinoma. They usually do not have characteristic clinical and imaging findings. The preoperative diagnosis of PBL is difficult and the diagnosis is based on biopsy and immunohistochemical staining. Diffuse large B-cell lymphoma is the most common histological diagnosis. We retrospectively analyzed four cases of PBL who attended at our center, between 1997 and 2019 and discussed to determine the common clinical features and therapy. These cases were originally treated by chemotherapy, that is, rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP/CHOP) or combined chemotherapy and radiotherapy and had recurrence in the central nervous system (CNS). Due to the high incidence of CNS involvement in these patients, many authors strongly believe that patients with aggressive forms of PBL should receive CNS prophylaxis, even in the early stages, as this may improve the outcome and significantly reduce the risk of a CNS relapse.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Primary Breast Lymphoma: A Case Series and Review

Sonkaria¹,

Tanwar²,

Saxena³

et al. 2020

IJCR

View full text Add to dashboard Cite

show abstract

“…Successful vacuumassisted biopsy of lym phoma can also be performed (17). Fluorescent in situ hybridization evaluates for the presence of chromosomal translocation (8,14), which is particularly relevant in the predominant DLBCL subtype, potentially affecting prognosis and therapeutic management (69,73,74).…”

Section: Percutaneous Interventional Techniques For Suspected Lymphomamentioning

confidence: 99%

“…PBL refers to primary lymphoma occurring in the breast in the absence of previously diagnosed extramammary lymphoma and in the absence of concurrent widespread disease. A rare diagnosis, PBL accounts for less than 1% of breast malignancies and less than 2% of extranodal nonHodgkin lymphomas (NHLs) (2,(4)(5)(6)(7)(8). PBL is more aggressive and has a worse prognosis in comparison to that of extranodal NHL of alternate sites, such as in the gastrointestinal tract (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review

et al. 2019

View full text Add to dashboard Cite

Breast lymphoma is a rare hematologic neoplasm that originates in the breast lymphoid tissue and includes primary breast lymphoma (PBL) and secondary breast lymphoma (SBL). PBL involves the breast lymphoid tissue in the absence of previously identified extra mammary lymphoma and widespread disease. SBL is the most common metastasis to the breast, accounting for 17% of metastatic disease to the breast. PBL and SBL usually demonstrate imaging phenotypes that overlap with those of primary breast carcinoma, which makes a prospective diagnosis of breast lymphoma challeng ing. These nonspecific imaging features include an iso to hyper dense oval mass or masses at mammography, a hypoechoic or mixedechogenicity hypervascular mass at US, an enhancing mass with type II kinetics at MRI, and high fluorine 18-fluorodeoxyglu cose avidity at PET. In cases of suspected lymphoma, reviewing the clinical history, using appropriate biopsy techniques, and evaluating for multiplicity, bilaterality, and distant disease are critical for diag nosis and management. A patient with PBL generally has an earlier clinical presentation with a palpable abnormality and a solitary im aging finding. In contrast, multiple masses in an older patient and an occult clinical presentation favor an SBL diagnosis. ©

show abstract

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma

Shichijo

Tatetsu

Nosaka

et al. 2022

eJHaem

View full text Add to dashboard Cite

There remains an unmet clinical need to identify which patients with diffuse large B‐cell lymphoma (DLBCL) would benefit from central nervous system (CNS) prophylaxis, due to the low positive predictive value (PPV; 10%–15%) of the currently available predictive models. To stratify patients at high risk of developing CNS relapse, we retrospectively analyzed 182 patients with DLBCL initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP), or a R‐CHOP‐like regimen. Among them, 17 patients relapsed with CNS involvement, and the 2‐year rate of CNS relapse was 7.9%. Upon carrying out multivariate analysis, ≥3 extranodal sites and elevated soluble interleukin‐2 receptor (sIL‐2R) levels at diagnosis were identified as independent risk factors for CNS relapse. The 2‐year and 3.5‐year rates of CNS relapse were 57.1% and 78.6%, respectively, in patients with both elevated sIL‐2R and ≥3 extranodal sites. Furthermore, combined use of these risk factors of both elevated sIL‐2R and ≥3 extranodal sites resulted in a high PPV (71.4%), negative predictive value (93.1%), and overall accuracy (92.3%) for undergoing CNS relapse. In conclusion, we propose a simple and valuable tool to predict patients with DLBCL at very high risk of CNS relapse.

show abstract

Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014

Cited by 27 publications

References 34 publications

Primary Breast Lymphoma: A Case Series and Review

Primary Breast Lymphoma: A Case Series and Review

Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma

Contact Info

Product

Resources

About